Previous close | 50.05 |
Open | 49.00 |
Bid | 82.45 |
Ask | 85.10 |
Strike | 185.00 |
Expiry date | 2024-06-21 |
Day's range | 49.00 - 50.05 |
Contract range | N/A |
Volume | |
Open interest | 9 |
Stock market investors brace for a big week of earnings and econ as Apple, Amazon, Big Pharma and The Fed all line up to deliver news.
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]